Philip Poortmans, MD, PhD 1 · Triple neg “Basal like” 15% Rec-, HER2+ “HER2 like” 12% This...
Transcript of Philip Poortmans, MD, PhD 1 · Triple neg “Basal like” 15% Rec-, HER2+ “HER2 like” 12% This...
![Page 1: Philip Poortmans, MD, PhD 1 · Triple neg “Basal like” 15% Rec-, HER2+ “HER2 like” 12% This study supports the spectrum hypothesis: • Local disease in Luminal-A • Mixed](https://reader030.fdocumento.com/reader030/viewer/2022040511/5e5d16b9cfb43d6e1a526646/html5/thumbnails/1.jpg)
1Philip Poortmans, MD, PhD
Ex-Presidente
Presidente
![Page 2: Philip Poortmans, MD, PhD 1 · Triple neg “Basal like” 15% Rec-, HER2+ “HER2 like” 12% This study supports the spectrum hypothesis: • Local disease in Luminal-A • Mixed](https://reader030.fdocumento.com/reader030/viewer/2022040511/5e5d16b9cfb43d6e1a526646/html5/thumbnails/2.jpg)
El Perito Moreno
Parque nacional de los glaciaresEl 4 de abril 2019
![Page 3: Philip Poortmans, MD, PhD 1 · Triple neg “Basal like” 15% Rec-, HER2+ “HER2 like” 12% This study supports the spectrum hypothesis: • Local disease in Luminal-A • Mixed](https://reader030.fdocumento.com/reader030/viewer/2022040511/5e5d16b9cfb43d6e1a526646/html5/thumbnails/3.jpg)
3
Debería el perfil molecular influenciar el
tratamiento locoregional?
![Page 4: Philip Poortmans, MD, PhD 1 · Triple neg “Basal like” 15% Rec-, HER2+ “HER2 like” 12% This study supports the spectrum hypothesis: • Local disease in Luminal-A • Mixed](https://reader030.fdocumento.com/reader030/viewer/2022040511/5e5d16b9cfb43d6e1a526646/html5/thumbnails/4.jpg)
4
No tengo ningún conflicto de interés.
![Page 5: Philip Poortmans, MD, PhD 1 · Triple neg “Basal like” 15% Rec-, HER2+ “HER2 like” 12% This study supports the spectrum hypothesis: • Local disease in Luminal-A • Mixed](https://reader030.fdocumento.com/reader030/viewer/2022040511/5e5d16b9cfb43d6e1a526646/html5/thumbnails/5.jpg)
5
Molecular subtyping & locoregional treatment
1. Introduction
2. Molecular subtyping & & locoregional treatment
3. Discussion
4. Conclusions
![Page 6: Philip Poortmans, MD, PhD 1 · Triple neg “Basal like” 15% Rec-, HER2+ “HER2 like” 12% This study supports the spectrum hypothesis: • Local disease in Luminal-A • Mixed](https://reader030.fdocumento.com/reader030/viewer/2022040511/5e5d16b9cfb43d6e1a526646/html5/thumbnails/6.jpg)
6
El manejo de los ganglios axilares: Una
batalla entre la cirugía y la radioterapia?
![Page 7: Philip Poortmans, MD, PhD 1 · Triple neg “Basal like” 15% Rec-, HER2+ “HER2 like” 12% This study supports the spectrum hypothesis: • Local disease in Luminal-A • Mixed](https://reader030.fdocumento.com/reader030/viewer/2022040511/5e5d16b9cfb43d6e1a526646/html5/thumbnails/7.jpg)
7https://kanker-actueel.nl/fda-ondersteunt-onderzoek-naar-personalised-medicine-op-basis-van-mutaties-ongeacht-in-welk-lichaamsdeel-de-kanker-zich-het-eerst-openbaart.html
RT RT
RT RT
Molecular subtypes & locoregional ttm: Introduction
![Page 8: Philip Poortmans, MD, PhD 1 · Triple neg “Basal like” 15% Rec-, HER2+ “HER2 like” 12% This study supports the spectrum hypothesis: • Local disease in Luminal-A • Mixed](https://reader030.fdocumento.com/reader030/viewer/2022040511/5e5d16b9cfb43d6e1a526646/html5/thumbnails/8.jpg)
8Bertucci F, et al. Cancer research 2005;65:2170-8.
Molecular subtypes & locoregional ttm: Introduction
![Page 9: Philip Poortmans, MD, PhD 1 · Triple neg “Basal like” 15% Rec-, HER2+ “HER2 like” 12% This study supports the spectrum hypothesis: • Local disease in Luminal-A • Mixed](https://reader030.fdocumento.com/reader030/viewer/2022040511/5e5d16b9cfb43d6e1a526646/html5/thumbnails/9.jpg)
9Proposed by St Gallen; ASCO; ESMO; …
Molecular subtypes & locoregional ttm: Introduction
![Page 10: Philip Poortmans, MD, PhD 1 · Triple neg “Basal like” 15% Rec-, HER2+ “HER2 like” 12% This study supports the spectrum hypothesis: • Local disease in Luminal-A • Mixed](https://reader030.fdocumento.com/reader030/viewer/2022040511/5e5d16b9cfb43d6e1a526646/html5/thumbnails/10.jpg)
10
Molecular subtyping & locoregional treatment
1. Introduction
2. Molecular subtyping & & locoregionaltreatment
3. Discussion
4. Conclusions
![Page 11: Philip Poortmans, MD, PhD 1 · Triple neg “Basal like” 15% Rec-, HER2+ “HER2 like” 12% This study supports the spectrum hypothesis: • Local disease in Luminal-A • Mixed](https://reader030.fdocumento.com/reader030/viewer/2022040511/5e5d16b9cfb43d6e1a526646/html5/thumbnails/11.jpg)
11Overgaard M, et al. Radiotherapy & Oncology 2007;82:247-53.
Molecular subtypes & locoregional ttm: Early experience
ABSOLUTELY
IDENTICAL!
Editorial
![Page 12: Philip Poortmans, MD, PhD 1 · Triple neg “Basal like” 15% Rec-, HER2+ “HER2 like” 12% This study supports the spectrum hypothesis: • Local disease in Luminal-A • Mixed](https://reader030.fdocumento.com/reader030/viewer/2022040511/5e5d16b9cfb43d6e1a526646/html5/thumbnails/12.jpg)
12Kyndi M, et al. Radiotherapy & Oncology 2009;90:74-79.
Molecular subtypes & locoregional ttm: Early experience
![Page 13: Philip Poortmans, MD, PhD 1 · Triple neg “Basal like” 15% Rec-, HER2+ “HER2 like” 12% This study supports the spectrum hypothesis: • Local disease in Luminal-A • Mixed](https://reader030.fdocumento.com/reader030/viewer/2022040511/5e5d16b9cfb43d6e1a526646/html5/thumbnails/13.jpg)
13Kyndi M, et al. Radiotherapy & Oncology 2009;90:74-79.
DBCG 82 b&c
1982 – 1990 n = 3083
Either: pN+
T3-T4
Invasion of the pectoral fascia
Al,l patients received CMF or Tamoxifen
MRM ® ± RT
Molecular subtypes & locoregional ttm: Early experience
![Page 14: Philip Poortmans, MD, PhD 1 · Triple neg “Basal like” 15% Rec-, HER2+ “HER2 like” 12% This study supports the spectrum hypothesis: • Local disease in Luminal-A • Mixed](https://reader030.fdocumento.com/reader030/viewer/2022040511/5e5d16b9cfb43d6e1a526646/html5/thumbnails/14.jpg)
14Kyndi M, et al. Radiotherapy & Oncology 2009;90:74-79.
DBCG 82 b&c
5 favourable criteria:
≤ 3 N+ ≤ 2 cm T G1
ER + Her-2-neu –
➔ Low risk = ≥ 4/5 favourable criteria
3 unfavourable criteria:
> 3 N+ > 5 cm T G3
➔ High risk = ≥ 2/3 unfavourable criteria
➔ Intermediate risk = all others
Molecular subtypes & locoregional ttm: Early experience
![Page 15: Philip Poortmans, MD, PhD 1 · Triple neg “Basal like” 15% Rec-, HER2+ “HER2 like” 12% This study supports the spectrum hypothesis: • Local disease in Luminal-A • Mixed](https://reader030.fdocumento.com/reader030/viewer/2022040511/5e5d16b9cfb43d6e1a526646/html5/thumbnails/15.jpg)
15Kyndi M, et al. Radiotherapy & Oncology 2009;90:74-79.
Molecular subtypes & locoregional ttm: Early experience
![Page 16: Philip Poortmans, MD, PhD 1 · Triple neg “Basal like” 15% Rec-, HER2+ “HER2 like” 12% This study supports the spectrum hypothesis: • Local disease in Luminal-A • Mixed](https://reader030.fdocumento.com/reader030/viewer/2022040511/5e5d16b9cfb43d6e1a526646/html5/thumbnails/16.jpg)
16Kyndi M, et al. Radiotherapy & Oncology 2009;90:74-79.
LRR
Molecular subtypes & locoregional ttm: Early experience
![Page 17: Philip Poortmans, MD, PhD 1 · Triple neg “Basal like” 15% Rec-, HER2+ “HER2 like” 12% This study supports the spectrum hypothesis: • Local disease in Luminal-A • Mixed](https://reader030.fdocumento.com/reader030/viewer/2022040511/5e5d16b9cfb43d6e1a526646/html5/thumbnails/17.jpg)
17Kyndi M, et al. Radiotherapy & Oncology 2009;90:74-79.
DSS
Molecular subtypes & locoregional ttm: Early experience
![Page 18: Philip Poortmans, MD, PhD 1 · Triple neg “Basal like” 15% Rec-, HER2+ “HER2 like” 12% This study supports the spectrum hypothesis: • Local disease in Luminal-A • Mixed](https://reader030.fdocumento.com/reader030/viewer/2022040511/5e5d16b9cfb43d6e1a526646/html5/thumbnails/18.jpg)
18Kyndi M, et al. Radiotherapy & Oncology 2009;90:74-79.
OS
Molecular subtypes & locoregional ttm: Early experience
![Page 19: Philip Poortmans, MD, PhD 1 · Triple neg “Basal like” 15% Rec-, HER2+ “HER2 like” 12% This study supports the spectrum hypothesis: • Local disease in Luminal-A • Mixed](https://reader030.fdocumento.com/reader030/viewer/2022040511/5e5d16b9cfb43d6e1a526646/html5/thumbnails/19.jpg)
19Kyndi M, et al. Radiotherapy & Oncology 2009;90:74-79.
Risk: Low Intermediate High
Treatment: (-) RT (-) RT (-) RT
LR at 5y: 11 → 0 26 → 5 50 → 14
DSS at 15y: 67 → 78 39 → 50 19 → 19
OS at 15y: 53 → 65 30 → 39 12 → 16
-11
+11
+12
-21
+11
+9
-36
+0
+4
➔ ~ 1/1 ~ 1/2 ~ 1/9
Molecular subtypes & locoregional ttm: Early experience
![Page 20: Philip Poortmans, MD, PhD 1 · Triple neg “Basal like” 15% Rec-, HER2+ “HER2 like” 12% This study supports the spectrum hypothesis: • Local disease in Luminal-A • Mixed](https://reader030.fdocumento.com/reader030/viewer/2022040511/5e5d16b9cfb43d6e1a526646/html5/thumbnails/20.jpg)
20Kyndi M, et al. JCO 2008;26:1419-14.
Molecular subtypes & locoregional ttm: Molecular based experience
The same DBCG 82 b&c cohort, N=1000
![Page 21: Philip Poortmans, MD, PhD 1 · Triple neg “Basal like” 15% Rec-, HER2+ “HER2 like” 12% This study supports the spectrum hypothesis: • Local disease in Luminal-A • Mixed](https://reader030.fdocumento.com/reader030/viewer/2022040511/5e5d16b9cfb43d6e1a526646/html5/thumbnails/21.jpg)
21Kyndi M, et al. JCO 2008;26:1419-14.
ER+ PgR+ HER2-
ER- PgR- HER2+
Molecular subtypes & locoregional ttm: Molecular based experience
![Page 22: Philip Poortmans, MD, PhD 1 · Triple neg “Basal like” 15% Rec-, HER2+ “HER2 like” 12% This study supports the spectrum hypothesis: • Local disease in Luminal-A • Mixed](https://reader030.fdocumento.com/reader030/viewer/2022040511/5e5d16b9cfb43d6e1a526646/html5/thumbnails/22.jpg)
22Kyndi M, et al. JCO 2008;26:1419-14.
ER+ PgR+ HER2 -
ER- PgR- HER2+
Molecular subtypes & locoregional ttm: Molecular based experience
![Page 23: Philip Poortmans, MD, PhD 1 · Triple neg “Basal like” 15% Rec-, HER2+ “HER2 like” 12% This study supports the spectrum hypothesis: • Local disease in Luminal-A • Mixed](https://reader030.fdocumento.com/reader030/viewer/2022040511/5e5d16b9cfb43d6e1a526646/html5/thumbnails/23.jpg)
23Kyndi M, et al. JCO 2008;26:1419-14.
Rec+, HER2-“Luminal A”
63%
Rec+, HER2+ “Luminal B”
10%
Triple neg “Basal like”
15%
Rec-, HER2+ “HER2 like”
12%
![Page 24: Philip Poortmans, MD, PhD 1 · Triple neg “Basal like” 15% Rec-, HER2+ “HER2 like” 12% This study supports the spectrum hypothesis: • Local disease in Luminal-A • Mixed](https://reader030.fdocumento.com/reader030/viewer/2022040511/5e5d16b9cfb43d6e1a526646/html5/thumbnails/24.jpg)
24Kyndi M, et al. JCO 2008;26:1419-14.
Rec+, HER2-“Luminal A”
63%
Rec+, HER2+ “Luminal B”
10%
Triple neg “Basal like”
15%
Rec-, HER2+ “HER2 like”
12%
This study supports the spectrum hypothesis:
• Local disease in Luminal-A
• Mixed in Luminal-B
• With adjuvant endocrine treatment & CMF
• Micrometastases in triple negative and HER-2
• Insufficient systemic treatment in the 80ties
To be explored further:
• Influence of adjuvant systemic treatments
• Role of radioresistance of Rec- and HER-2
![Page 25: Philip Poortmans, MD, PhD 1 · Triple neg “Basal like” 15% Rec-, HER2+ “HER2 like” 12% This study supports the spectrum hypothesis: • Local disease in Luminal-A • Mixed](https://reader030.fdocumento.com/reader030/viewer/2022040511/5e5d16b9cfb43d6e1a526646/html5/thumbnails/25.jpg)
25Kyndi M, et al. JCO 2008;26:1419-14.
Rec+, HER2-“Luminal A”
63%
Rec+, HER2+ “Luminal B”
10%
Triple neg “Basal like”
15%
Rec-, HER2+ “HER2 like”
12%
This study supports the spectrum hypothesis:
• Local disease in Luminal-A
• Mixed in Luminal-B
• With adjuvant endocrine treatment & CMF
• Micrometastases in triple negative and HER-2
• Insufficient systemic treatment in the 80ties
To be explored further:
• Influence of adjuvant systemic treatments
• Role of radioresistance of Rec- and HER-2
![Page 26: Philip Poortmans, MD, PhD 1 · Triple neg “Basal like” 15% Rec-, HER2+ “HER2 like” 12% This study supports the spectrum hypothesis: • Local disease in Luminal-A • Mixed](https://reader030.fdocumento.com/reader030/viewer/2022040511/5e5d16b9cfb43d6e1a526646/html5/thumbnails/26.jpg)
26Kyndi M, et al. JCO 2008;26:1419-14.
Rec+, HER2-“Luminal A”
63%
Rec+, HER2+ “Luminal B”
10%
Triple neg “Basal like”
15%
Rec-, HER2+ “HER2 like”
12%
This study supports the spectrum hypothesis:
• Local disease in Luminal-A
• Mixed in Luminal-B
• With adjuvant endocrine treatment & CMF
• Micrometastases in triple negative and HER-2
• Insufficient systemic treatment in the 80ties
To be explored further:
• Influence of adjuvant systemic treatments
• Role of radioresistance of Rec- and HER-2
![Page 27: Philip Poortmans, MD, PhD 1 · Triple neg “Basal like” 15% Rec-, HER2+ “HER2 like” 12% This study supports the spectrum hypothesis: • Local disease in Luminal-A • Mixed](https://reader030.fdocumento.com/reader030/viewer/2022040511/5e5d16b9cfb43d6e1a526646/html5/thumbnails/27.jpg)
27Nguyen PL, et al. JCO 2008;26:2373-08.
BCS 1998-2001; N=793
FU = 70 months
Systemic therapy:
Chemotherapy 88% of N+ and 29% of N0
Hormonal therapy to 88% of patients with ER+ / PgR+ disease
No trastuzumab
Radiation therapy:
WBI + boost
Supraclavicular / axillary field if N2-disease
N = 18 isolated located recurrences
• Luminal A: ER+ or PgR+ and HER2-
• Luminal B: ER+ or PgR+ and HER2+
• HER2: ER- or PgR- and HER2+
• Basal: triple neg
Molecular subtypes & locoregional ttm: Molecular based experience
![Page 28: Philip Poortmans, MD, PhD 1 · Triple neg “Basal like” 15% Rec-, HER2+ “HER2 like” 12% This study supports the spectrum hypothesis: • Local disease in Luminal-A • Mixed](https://reader030.fdocumento.com/reader030/viewer/2022040511/5e5d16b9cfb43d6e1a526646/html5/thumbnails/28.jpg)
28Nguyen PL, et al. JCO 2008;26:2373-08.
Local recurrence
Molecular subtypes & locoregional ttm: Molecular based experience
![Page 29: Philip Poortmans, MD, PhD 1 · Triple neg “Basal like” 15% Rec-, HER2+ “HER2 like” 12% This study supports the spectrum hypothesis: • Local disease in Luminal-A • Mixed](https://reader030.fdocumento.com/reader030/viewer/2022040511/5e5d16b9cfb43d6e1a526646/html5/thumbnails/29.jpg)
29Nguyen PL, et al. JCO 2008;26:2373-08.
Local recurrence
Distant metastasis
Molecular subtypes & locoregional ttm: Molecular based experience
![Page 30: Philip Poortmans, MD, PhD 1 · Triple neg “Basal like” 15% Rec-, HER2+ “HER2 like” 12% This study supports the spectrum hypothesis: • Local disease in Luminal-A • Mixed](https://reader030.fdocumento.com/reader030/viewer/2022040511/5e5d16b9cfb43d6e1a526646/html5/thumbnails/30.jpg)
30Nguyen PL, et al. JCO 2008;26:2373-08.
Local recurrence
Distant metastasis
Luminal A has a particularly
low recurrence rate
Molecular subtypes & locoregional ttm: Molecular based experience
![Page 31: Philip Poortmans, MD, PhD 1 · Triple neg “Basal like” 15% Rec-, HER2+ “HER2 like” 12% This study supports the spectrum hypothesis: • Local disease in Luminal-A • Mixed](https://reader030.fdocumento.com/reader030/viewer/2022040511/5e5d16b9cfb43d6e1a526646/html5/thumbnails/31.jpg)
31Mamounas EP, et al. JCO 2010;28:1677-83.
BCS+RT or MRM 1982-1993; 2 randomised trials:
• B-14 : 5 year Tamoxifem vs placebo, later on Tam 5 vs 10 y
• B-20 : Tamoxifen +/- chemo
✓ The 21-gene OncotypeDX recurrence score (RS) assay can predict distant
recurrence risk in patients with tumors ER+ and N0
? Can the 21-gene assay predict locoregional recurrence risk?
Molecular subtypes & locoregional ttm: Molecular based experience
![Page 32: Philip Poortmans, MD, PhD 1 · Triple neg “Basal like” 15% Rec-, HER2+ “HER2 like” 12% This study supports the spectrum hypothesis: • Local disease in Luminal-A • Mixed](https://reader030.fdocumento.com/reader030/viewer/2022040511/5e5d16b9cfb43d6e1a526646/html5/thumbnails/32.jpg)
32Mamounas EP, et al. JCO 2010;28:1677-83.
N=895
Molecular subtypes & locoregional ttm: Molecular based experience
![Page 33: Philip Poortmans, MD, PhD 1 · Triple neg “Basal like” 15% Rec-, HER2+ “HER2 like” 12% This study supports the spectrum hypothesis: • Local disease in Luminal-A • Mixed](https://reader030.fdocumento.com/reader030/viewer/2022040511/5e5d16b9cfb43d6e1a526646/html5/thumbnails/33.jpg)
33Mamounas EP, et al. JCO 2010;28:1677-83.
N=895
N=355
Molecular subtypes & locoregional ttm: Molecular based experience
![Page 34: Philip Poortmans, MD, PhD 1 · Triple neg “Basal like” 15% Rec-, HER2+ “HER2 like” 12% This study supports the spectrum hypothesis: • Local disease in Luminal-A • Mixed](https://reader030.fdocumento.com/reader030/viewer/2022040511/5e5d16b9cfb43d6e1a526646/html5/thumbnails/34.jpg)
34Mamounas EP, et al. JCO 2010;28:1677-83.
N=895
N=355
N=424
Molecular subtypes & locoregional ttm: Molecular based experience
![Page 35: Philip Poortmans, MD, PhD 1 · Triple neg “Basal like” 15% Rec-, HER2+ “HER2 like” 12% This study supports the spectrum hypothesis: • Local disease in Luminal-A • Mixed](https://reader030.fdocumento.com/reader030/viewer/2022040511/5e5d16b9cfb43d6e1a526646/html5/thumbnails/35.jpg)
35Mamounas EP, et al. JCO 2010;28:1677-83.
N=895
N=355
N=424
Conclusion:
The 21-gene assay locoregional recurrence risk
• In this group of ER+ and N0 patients
• With this adjuvant systemic treatment
Further studies required:
• To confirm the low LRR risk group ➔ without RT
• To define the high LRR risk group ➔ new RT indications
Molecular subtypes & locoregional ttm: Molecular based experience
![Page 36: Philip Poortmans, MD, PhD 1 · Triple neg “Basal like” 15% Rec-, HER2+ “HER2 like” 12% This study supports the spectrum hypothesis: • Local disease in Luminal-A • Mixed](https://reader030.fdocumento.com/reader030/viewer/2022040511/5e5d16b9cfb43d6e1a526646/html5/thumbnails/36.jpg)
36Chen J, et al. WJSO 2014;12:212.
N = 21.654
Molecular subtypes & locoregional ttm: Molecular based experience
![Page 37: Philip Poortmans, MD, PhD 1 · Triple neg “Basal like” 15% Rec-, HER2+ “HER2 like” 12% This study supports the spectrum hypothesis: • Local disease in Luminal-A • Mixed](https://reader030.fdocumento.com/reader030/viewer/2022040511/5e5d16b9cfb43d6e1a526646/html5/thumbnails/37.jpg)
37Chen J, et al. WJSO 2014;12:212.
Molecular subtypes & locoregional ttm: Molecular based experience
![Page 38: Philip Poortmans, MD, PhD 1 · Triple neg “Basal like” 15% Rec-, HER2+ “HER2 like” 12% This study supports the spectrum hypothesis: • Local disease in Luminal-A • Mixed](https://reader030.fdocumento.com/reader030/viewer/2022040511/5e5d16b9cfb43d6e1a526646/html5/thumbnails/38.jpg)
38Chen J, et al. WJSO 2014;12:212.
Molecular subtypes & locoregional ttm: Molecular based experience
![Page 39: Philip Poortmans, MD, PhD 1 · Triple neg “Basal like” 15% Rec-, HER2+ “HER2 like” 12% This study supports the spectrum hypothesis: • Local disease in Luminal-A • Mixed](https://reader030.fdocumento.com/reader030/viewer/2022040511/5e5d16b9cfb43d6e1a526646/html5/thumbnails/39.jpg)
39Abdulkarin BS, et al. JCO 2011;29:2852-8.
Single institution; N = 768
Molecular subtypes & locoregional ttm: Molecular based experience
![Page 40: Philip Poortmans, MD, PhD 1 · Triple neg “Basal like” 15% Rec-, HER2+ “HER2 like” 12% This study supports the spectrum hypothesis: • Local disease in Luminal-A • Mixed](https://reader030.fdocumento.com/reader030/viewer/2022040511/5e5d16b9cfb43d6e1a526646/html5/thumbnails/40.jpg)
40Abdulkarin BS, et al. JCO 2011;29:2852-8.
Molecular subtypes & locoregional ttm: Molecular based experience
![Page 41: Philip Poortmans, MD, PhD 1 · Triple neg “Basal like” 15% Rec-, HER2+ “HER2 like” 12% This study supports the spectrum hypothesis: • Local disease in Luminal-A • Mixed](https://reader030.fdocumento.com/reader030/viewer/2022040511/5e5d16b9cfb43d6e1a526646/html5/thumbnails/41.jpg)
41Abdulkarin BS, et al. JCO 2011;29:2852-8.
Molecular subtypes & locoregional ttm: Molecular based experience
![Page 42: Philip Poortmans, MD, PhD 1 · Triple neg “Basal like” 15% Rec-, HER2+ “HER2 like” 12% This study supports the spectrum hypothesis: • Local disease in Luminal-A • Mixed](https://reader030.fdocumento.com/reader030/viewer/2022040511/5e5d16b9cfb43d6e1a526646/html5/thumbnails/42.jpg)
42Rezai M, et al. The Breast 2015;24:380-94.
Molecular subtypes & locoregional ttm: Molecular based experience
![Page 43: Philip Poortmans, MD, PhD 1 · Triple neg “Basal like” 15% Rec-, HER2+ “HER2 like” 12% This study supports the spectrum hypothesis: • Local disease in Luminal-A • Mixed](https://reader030.fdocumento.com/reader030/viewer/2022040511/5e5d16b9cfb43d6e1a526646/html5/thumbnails/43.jpg)
43Rezai M, et al. The Breast 2015;24:380-94.
0
100
200
300
400
500
600
700
Lum A Lum B (Her 2 Neg) TNP Her 2 + Other
Number Local recurrence
LRR: 2.2% 2.7% 11.3% 9.3%Lum B HER-2 +: 3.8%
Molecular subtypes & locoregional ttm: Molecular based experience
![Page 44: Philip Poortmans, MD, PhD 1 · Triple neg “Basal like” 15% Rec-, HER2+ “HER2 like” 12% This study supports the spectrum hypothesis: • Local disease in Luminal-A • Mixed](https://reader030.fdocumento.com/reader030/viewer/2022040511/5e5d16b9cfb43d6e1a526646/html5/thumbnails/44.jpg)
44
1. Introduction
2. Molecular subtyping & locoregional treatment
3. Discussion
4. Conclusions
Molecular subtyping & locoregional treatment
![Page 45: Philip Poortmans, MD, PhD 1 · Triple neg “Basal like” 15% Rec-, HER2+ “HER2 like” 12% This study supports the spectrum hypothesis: • Local disease in Luminal-A • Mixed](https://reader030.fdocumento.com/reader030/viewer/2022040511/5e5d16b9cfb43d6e1a526646/html5/thumbnails/45.jpg)
45
Molecular subtypes & locoregional ttm: Discussion
Risk factors for local recurrence:
• After mastectomy
• After lumpectomy +/- WBRT
• After lumpectomy +/- WBRT +/- boost
• After APBI
![Page 46: Philip Poortmans, MD, PhD 1 · Triple neg “Basal like” 15% Rec-, HER2+ “HER2 like” 12% This study supports the spectrum hypothesis: • Local disease in Luminal-A • Mixed](https://reader030.fdocumento.com/reader030/viewer/2022040511/5e5d16b9cfb43d6e1a526646/html5/thumbnails/46.jpg)
46Poortmans P. Lancet. 2014 Jun 21;383(9935):2104-6.
1/4
1/2-3
1/1.5
1/
1/4
Interaction systemic and locoregional treatments
Molecular subtypes & locoregional ttm: Discussion
![Page 47: Philip Poortmans, MD, PhD 1 · Triple neg “Basal like” 15% Rec-, HER2+ “HER2 like” 12% This study supports the spectrum hypothesis: • Local disease in Luminal-A • Mixed](https://reader030.fdocumento.com/reader030/viewer/2022040511/5e5d16b9cfb43d6e1a526646/html5/thumbnails/47.jpg)
47Poortmans P. Lancet. 2014 Jun 21;383(9935):2104-6.
Triple -/Her2 type Lum B type Lum A type
NC/PD PR CR
Molecular subtypes & locoregional ttm: Discussion
![Page 48: Philip Poortmans, MD, PhD 1 · Triple neg “Basal like” 15% Rec-, HER2+ “HER2 like” 12% This study supports the spectrum hypothesis: • Local disease in Luminal-A • Mixed](https://reader030.fdocumento.com/reader030/viewer/2022040511/5e5d16b9cfb43d6e1a526646/html5/thumbnails/48.jpg)
48Poortmans P. Lancet. 2014 Jun 21;383(9935):2104-6.
Triple -/Her2 type Lum B type Lum A type
NC/PD PR CR
Lum A; minor R
Molecular subtypes & locoregional ttm: Discussion
![Page 49: Philip Poortmans, MD, PhD 1 · Triple neg “Basal like” 15% Rec-, HER2+ “HER2 like” 12% This study supports the spectrum hypothesis: • Local disease in Luminal-A • Mixed](https://reader030.fdocumento.com/reader030/viewer/2022040511/5e5d16b9cfb43d6e1a526646/html5/thumbnails/49.jpg)
49Poortmans P. Lancet. 2014 Jun 21;383(9935):2104-6.
Triple -/Her2 type Lum B type Lum A type
NC/PD PR CR
---; ypCR
Molecular subtypes & locoregional ttm: Discussion
![Page 50: Philip Poortmans, MD, PhD 1 · Triple neg “Basal like” 15% Rec-, HER2+ “HER2 like” 12% This study supports the spectrum hypothesis: • Local disease in Luminal-A • Mixed](https://reader030.fdocumento.com/reader030/viewer/2022040511/5e5d16b9cfb43d6e1a526646/html5/thumbnails/50.jpg)
50Poortmans P. Lancet. 2014 Jun 21;383(9935):2104-6.
Triple -/Her2 type Lum B type Lum A type
NC/PD PR CR---; NC
Molecular subtypes & locoregional ttm: Discussion
![Page 51: Philip Poortmans, MD, PhD 1 · Triple neg “Basal like” 15% Rec-, HER2+ “HER2 like” 12% This study supports the spectrum hypothesis: • Local disease in Luminal-A • Mixed](https://reader030.fdocumento.com/reader030/viewer/2022040511/5e5d16b9cfb43d6e1a526646/html5/thumbnails/51.jpg)
20th century21st centuryL. van ‘t Veer et al Nature 415, p530-536, 2002 M. vd Vijver et al, NEJM 347; 1999-2009, 2002
The « omics" are here!
![Page 52: Philip Poortmans, MD, PhD 1 · Triple neg “Basal like” 15% Rec-, HER2+ “HER2 like” 12% This study supports the spectrum hypothesis: • Local disease in Luminal-A • Mixed](https://reader030.fdocumento.com/reader030/viewer/2022040511/5e5d16b9cfb43d6e1a526646/html5/thumbnails/52.jpg)
52Iyer et al Science 1999 83-7; Chang et al PLoS Biology 2004 Feb 2 2 1- 9
In vitro Wound Model – 516 genes
Prognostic Significance in
• Breast
• Lung
• Gastric cancer
Wound Response Signature
Molecular subtypes & locoregional ttm: Discussion
![Page 53: Philip Poortmans, MD, PhD 1 · Triple neg “Basal like” 15% Rec-, HER2+ “HER2 like” 12% This study supports the spectrum hypothesis: • Local disease in Luminal-A • Mixed](https://reader030.fdocumento.com/reader030/viewer/2022040511/5e5d16b9cfb43d6e1a526646/html5/thumbnails/53.jpg)
53Nuyten DS et al, Breast Cancer Res. 2006;8(5):R62.
Predict of Local Recurrence in Early Breast Cancer
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1
0 2 4 6 8 10 12
Activated
Quiescent
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1
0 2 4 6 8 10 12
Activated
Quiescent P=0.0005P=0.00014
Training Validation
0
0.2
0.4
0.6
0.8
1
1.2
0 5 10 15 20
timelokr_1
Pro
bab
ilit
y
High Risk
Low Risk0
0.2
0.4
0.6
0.8
1
1.2
0 5 10 15 20
High Risk
Low Risk
Molecular subtypes & locoregional ttm: Discussion
![Page 54: Philip Poortmans, MD, PhD 1 · Triple neg “Basal like” 15% Rec-, HER2+ “HER2 like” 12% This study supports the spectrum hypothesis: • Local disease in Luminal-A • Mixed](https://reader030.fdocumento.com/reader030/viewer/2022040511/5e5d16b9cfb43d6e1a526646/html5/thumbnails/54.jpg)
54
1. Introduction
2. Molecular subtyping & locoregional treatment
3. Discussion
4. Conclusions
Molecular subtyping & locoregional treatment
![Page 55: Philip Poortmans, MD, PhD 1 · Triple neg “Basal like” 15% Rec-, HER2+ “HER2 like” 12% This study supports the spectrum hypothesis: • Local disease in Luminal-A • Mixed](https://reader030.fdocumento.com/reader030/viewer/2022040511/5e5d16b9cfb43d6e1a526646/html5/thumbnails/55.jpg)
55
✓ Validated risk factors are known
• After mastectomy
• After BCS +/- WBRT +/- boost
• After APBI
✓ Risk factors change over time ➔ role of
systemic treatment
Molecular subtypes & locoregional ttm: Conclusions
![Page 56: Philip Poortmans, MD, PhD 1 · Triple neg “Basal like” 15% Rec-, HER2+ “HER2 like” 12% This study supports the spectrum hypothesis: • Local disease in Luminal-A • Mixed](https://reader030.fdocumento.com/reader030/viewer/2022040511/5e5d16b9cfb43d6e1a526646/html5/thumbnails/56.jpg)
56Bouganim N, et al. Breast Cancer Res Treat 2013;139:603–6.
Advances in treatment have differentially reduced the proportion
of LRR compared with DR ➔ down to 10-15% of all recurrences
➔ influence design new clinical trials.
Evolution of sites of recurrence after EBC over the last 20 years
Molecular subtypes & locoregional ttm: Conclusions
![Page 57: Philip Poortmans, MD, PhD 1 · Triple neg “Basal like” 15% Rec-, HER2+ “HER2 like” 12% This study supports the spectrum hypothesis: • Local disease in Luminal-A • Mixed](https://reader030.fdocumento.com/reader030/viewer/2022040511/5e5d16b9cfb43d6e1a526646/html5/thumbnails/57.jpg)
57
Still a lot of work to be done!• Predictive molecular and genetic testing of normal tissue
and tumour responsiveness.
• The role of the immune system and host response.
• Test general hypotheses relating to radiation genomics and normal tissue responses.
• Large databases incl radionomics
• Nanoparticles as radiosensitisers.
• Sequential/serial biopsies.
• Overall treatment time.
Molecular subtypes & locoregional ttm: Conclusions
![Page 58: Philip Poortmans, MD, PhD 1 · Triple neg “Basal like” 15% Rec-, HER2+ “HER2 like” 12% This study supports the spectrum hypothesis: • Local disease in Luminal-A • Mixed](https://reader030.fdocumento.com/reader030/viewer/2022040511/5e5d16b9cfb43d6e1a526646/html5/thumbnails/58.jpg)
58
Molecular subtypes & locoregional ttm: Conclusions
![Page 59: Philip Poortmans, MD, PhD 1 · Triple neg “Basal like” 15% Rec-, HER2+ “HER2 like” 12% This study supports the spectrum hypothesis: • Local disease in Luminal-A • Mixed](https://reader030.fdocumento.com/reader030/viewer/2022040511/5e5d16b9cfb43d6e1a526646/html5/thumbnails/59.jpg)
59
• The molecular subtype influences the recurrence risk ...
• ... as well as the relative distribution of recurrences!
• Systemic treatments modify the recurrence risks and distribution ...
• ... and thereby modify the contribution of optimising locoregionalcontrol!
• Probably most benefit of locoregional ttm on OS for patients with low-risk tumours (Lum-A) and those treated with effective systemic treatment (Her2; TN)
Take home messages
Molecular subtypes & locoregional ttm: THM
![Page 60: Philip Poortmans, MD, PhD 1 · Triple neg “Basal like” 15% Rec-, HER2+ “HER2 like” 12% This study supports the spectrum hypothesis: • Local disease in Luminal-A • Mixed](https://reader030.fdocumento.com/reader030/viewer/2022040511/5e5d16b9cfb43d6e1a526646/html5/thumbnails/60.jpg)
60
• The molecular subtype influences the recurrence risk ...
• ... as well as the relative distribution of recurrences!
• Systemic treatments modify the recurrence risks and distribution ...
• ... and thereby modify the contribution of optimising locoregional control!
• Probably most benefit of locoregional ttm on OS for patients with low-risk tumours (Lum-A) and those treated with effective systemic treatment (Her2; TN)
Take home messages
Molecular subtypes & locoregional ttm: THM
![Page 61: Philip Poortmans, MD, PhD 1 · Triple neg “Basal like” 15% Rec-, HER2+ “HER2 like” 12% This study supports the spectrum hypothesis: • Local disease in Luminal-A • Mixed](https://reader030.fdocumento.com/reader030/viewer/2022040511/5e5d16b9cfb43d6e1a526646/html5/thumbnails/61.jpg)
61
• The molecular subtype influences the recurrence risk ...
• ... as well as the relative distribution of recurrences!
• Systemic treatments modify the recurrence risks and distribution ...
• ... and thereby modify the contribution of optimising locoregionalcontrol!
• Probably most benefit of locoregional ttm on OS for patients with low-risk tumours (Lum-A) and those treated with effective systemic treatment (Her2; TN)
Take home messages
Molecular subtypes & locoregional ttm: THM
![Page 62: Philip Poortmans, MD, PhD 1 · Triple neg “Basal like” 15% Rec-, HER2+ “HER2 like” 12% This study supports the spectrum hypothesis: • Local disease in Luminal-A • Mixed](https://reader030.fdocumento.com/reader030/viewer/2022040511/5e5d16b9cfb43d6e1a526646/html5/thumbnails/62.jpg)
62
- Jens Overgaard
- Harry Bartelink
- Birgitte Offersen
- Orit Kaidar-Person
- Paul Span
- Charlotte Coles
- Liesbeth Boersma
- Sandra Hol
- Icro Meattini
- And many others!
Molecular subtypes & locoregional ttm: Acknowledgements
![Page 63: Philip Poortmans, MD, PhD 1 · Triple neg “Basal like” 15% Rec-, HER2+ “HER2 like” 12% This study supports the spectrum hypothesis: • Local disease in Luminal-A • Mixed](https://reader030.fdocumento.com/reader030/viewer/2022040511/5e5d16b9cfb43d6e1a526646/html5/thumbnails/63.jpg)
El Perito Moreno
El GlaciariumEl 5 de abril 2019
![Page 64: Philip Poortmans, MD, PhD 1 · Triple neg “Basal like” 15% Rec-, HER2+ “HER2 like” 12% This study supports the spectrum hypothesis: • Local disease in Luminal-A • Mixed](https://reader030.fdocumento.com/reader030/viewer/2022040511/5e5d16b9cfb43d6e1a526646/html5/thumbnails/64.jpg)
64